300404 博济医药
已收盘 06-12 15:00:00
资讯
新帖
简况
博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等
智通财经 · 06-08
博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等
博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%
证券之星 · 06-01
博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%
博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%
证券之星 · 05-18
博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%
博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%
证券之星 · 05-13
博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%
每周股票复盘：博济医药（300404）一季度订单增74.36%
证券之星 · 05-03
每周股票复盘：博济医药（300404）一季度订单增74.36%
博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与
证券之星 · 04-27
博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与
博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
证券之星 · 04-26
博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大
博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%
智通财经 · 04-24
博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%
博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务
证券之星 · 04-08
博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务
博济医药最新公告：全资子公司获得药物临床试验批准通知书
证券之星 · 04-03
博济医药最新公告：全资子公司获得药物临床试验批准通知书
博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%
证券之星 · 03-24
博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%
博济医药（300404）披露首次减持回购股份公告，3月19日股价下跌2.74%
证券之星 · 03-19
博济医药（300404）披露首次减持回购股份公告，3月19日股价下跌2.74%
博济医药：服务植入式脑深部刺激系统等脑科医疗器械
证券之星 · 03-18
博济医药：服务植入式脑深部刺激系统等脑科医疗器械
股市必读：博济医药（300404）3月17日董秘有最新回复
证券之星 · 03-18
股市必读：博济医药（300404）3月17日董秘有最新回复
股市必读：博济医药（300404）3月12日董秘有最新回复
证券之星 · 03-13
股市必读：博济医药（300404）3月12日董秘有最新回复
博济医药：2025年前三季度公司营业收入同比增长5.06%
证券之星 · 03-03
博济医药：2025年前三季度公司营业收入同比增长5.06%
博济医药最新公告：拟以集中竞价方式减持不超过266.7万股回购股份
证券之星 · 02-24
博济医药最新公告：拟以集中竞价方式减持不超过266.7万股回购股份
博济医药：公司重视市值管理并提升经营质量
证券之星 · 01-20
博济医药：公司重视市值管理并提升经营质量
博济医药：探索AI技术在药物研发中应用
证券之星 · 01-16
博济医药：探索AI技术在药物研发中应用
博济医药：努力提升盈利能力回馈投资者
证券之星 · 01-16
博济医药：努力提升盈利能力回馈投资者
公司概况
公司名称：
博济医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2015-04-24
主营业务：
博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床前研究服务、临床研究服务、其他咨询服务、CDMO服务。
发行价格：
12.87
{"stockData":{"symbol":"300404","market":"SZ","secType":"STK","nameCN":"博济医药","latestPrice":8.37,"timestamp":1781247834000,"preClose":8.33,"halted":0,"volume":6674166,"delay":0,"changeRate":0.0048,"floatShares":286000000,"shares":386000000,"eps":0.1117,"marketStatus":"已收盘","change":0.04,"latestTime":"06-12 15:00:00","open":8.39,"high":8.5,"low":8.25,"amount":55954400,"amplitude":0.03,"askPrice":8.38,"askSize":427,"bidPrice":8.37,"bidSize":457,"shortable":0,"etf":0,"ttmEps":0.1117,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781487000000},"marketStatusCode":5,"adr":0,"adjPreClose":8.33,"symbolType":"stock","openAndCloseTimeList":[[1781227800000,1781235000000],[1781240400000,1781247600000]],"highLimit":9.16,"lowLimit":7.5,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":385748938,"isCdr":false,"pbRate":3.01,"roa":"--","peRate":74.932856,"roe":"1.59%","epsLYR":0.0794,"committee":-0.036106,"marketValue":3229000000,"turnoverRate":0.0234,"status":0,"floatMarketCap":2390000000},"requestUrl":"/m/hq/s/300404/wiki","defaultTab":"wiki","newsList":[{"id":"2641879934","title":"博济医药(300404.SZ)拟定增募资不超4.47亿元 用于中药创新药研发项目等","url":"https://stock-news.laohu8.com/highlight/detail?id=2641879934","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641879934?lang=zh_cn&edition=full","pubTime":"2026-06-08 21:46","pubTimestamp":1780926415,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布公告，公司拟向不超过35名符合中国证监会规定条件的特定投资者发行A股股票，发行募集资金总额不超过4.47亿元，扣除发行费用后拟将全部用于：药物评价中心扩建升级项目、中药创新药研发项目、医药研发大数据智能一体化平台项目、SMO中心建设项目、补充流动资金。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300404","BK1574","BK0216","06978","BK1161","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640950611","title":"博济医药（300404）披露部分限制性股票回购注销完成公告，6月1日股价上涨0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640950611","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640950611?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:24","pubTimestamp":1780323865,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，博济医药报收于10.0元，较前一交易日上涨0.3%，最新总市值为38.59亿元。近日，博济医药科技股份有限公司发布《关于部分限制性股票回购注销完成的公告》。本次回购注销完成后，公司总股本由385,975,208股减少至385,745,208股，公司股权分布仍具备上市条件，不影响公司管理团队稳定性及正常经营。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041098.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636506074","title":"博济医药（300404）披露2025年年度股东会决议公告，5月18日股价上涨0.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636506074","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636506074?lang=zh_cn&edition=full","pubTime":"2026-05-18 22:28","pubTimestamp":1779114503,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘，博济医药报收于10.7元，较前一交易日上涨0.38%，最新总市值为41.29亿元。该股当日开盘10.59元，最高10.75元，最低10.45元，成交额达1.07亿元，换手率为3.52%。近日，博济医药科技股份有限公司发布《2025年年度股东会决议公告》。会议表决程序合法，所有议案均获通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800037657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635200447","title":"博济医药（300404）披露2023年向特定对象发行股票之保荐总结报告书，5月13日股价下跌0.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635200447","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635200447?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:58","pubTimestamp":1778666339,"startTime":"0","endTime":"0","summary":"截至2026年5月13日收盘，博济医药报收于10.8元，较前一交易日下跌0.18%，最新总市值为41.67亿元。博济医药于近日披露《广发证券股份有限公司关于公司2023年向特定对象发行股票之保荐总结报告书》。公告显示，博济医药科技股份有限公司2023年向特定对象发行A股股票11,759,601股，发行价格7.03元/股，募集资金净额78,647,586.29元，于2023年12月8日在深圳证券交易所上市。广发证券作为保荐人，持续督导期至2025年12月31日届满，期间公司未发生重大事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300033369.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632260896","title":"每周股票复盘：博济医药（300404）一季度订单增74.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632260896","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632260896?lang=zh_cn&edition=full","pubTime":"2026-05-03 08:23","pubTimestamp":1777767791,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，博济医药报收于10.74元，较上周的10.19元上涨5.4%。本周，博济医药4月28日盘中最高价报11.16元。4月29日盘中最低价报10.43元。AI布局方面，引入第三方AI工具优化患者招募、方案设计、风险监查与数据管理，并组建AI团队自主开发，推动临床研究数字化与智能化转型。化药2.2类“氟康唑滴耳液”2025年取得IND，近期已对外转让。2025年及2026年第一季度，公司三费费用率均同比下降，随营收规模扩大，费用率预计进一步下降。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050300002080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630235501","title":"博济医药：4月26日接受机构调研，西部证券、青榕资管等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2630235501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630235501?lang=zh_cn&edition=full","pubTime":"2026-04-27 11:01","pubTimestamp":1777258903,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年4月27日博济医药发布公告称公司于2026年4月26日接受机构调研，西部证券、青榕资管、万汇投资、进门财经、光大医药、申万宏源、国信证券、中泰证券、国泰海通、兴业证券、尚诚资管、中金公司、中信期货参与。博济医药2026年一季报显示，一季度公司主营收入2.2亿元，同比上升58.54%；归母净利润1646.08万元，同比上升322.01%；扣非净利润1370.84万元，同比上升707.37%；负债率34.06%，投资收益44.32万元，财务费用21.63万元，毛利率28.45%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700015472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0183","BK0216","BK0188","002673","300404","BK0028","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630280723","title":"博济医药（300404）2026年一季报简析：营收净利润同比双双增长，公司应收账款体量较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2630280723","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630280723?lang=zh_cn&edition=full","pubTime":"2026-04-26 06:27","pubTimestamp":1777156057,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博济医药发布2026年一季报。截至本报告期末，公司营业总收入2.2亿元，同比上升58.54%，归母净利润1646.08万元，同比上升322.01%。本报告期博济医药公司应收账款体量较大，当期应收账款占最新年报归母净利润比达675.58%。本次财报公布的各项数据指标表现尚佳。去年的净利率为3.79%，算上全部成本后，公司产品或服务的附加值不高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600003726.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629892823","title":"博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629892823","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629892823?lang=zh_cn&edition=full","pubTime":"2026-04-24 23:03","pubTimestamp":1777043014,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博济医药(300404.SZ)发布2026年第一季度报告，该公司营业收入为2.2亿元，同比增长58.54%。归属于上市公司股东的净利润为1646.08万元，同比增长322.01%。归属于上市公司股东的扣除非经常性损益的净利润为1370.84万元，同比增长707.37%。基本每股收益为0.043元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博济医药(300404.SZ)发布一季度业绩，归母净利润1646.08万元，增长322.01%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625999270","title":"博济医药：公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务","url":"https://stock-news.laohu8.com/highlight/detail?id=2625999270","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625999270?lang=zh_cn&edition=full","pubTime":"2026-04-08 11:34","pubTimestamp":1775619242,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药04月07日在投资者关系平台上答复投资者关心的问题。博济医药回复：您好，目前公司没有与药石科技合作，公司专注于为医药企业提供药品、医疗器械的全流程“一站式”研发外包服务，包括：临床前研究服务、临床研究服务、其他咨询服务以及CDMO服务，其中临床研究服务为公司最主要的业务板块，占公司整体营业收入80%以上。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800014274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","09996","BK1222","BK1100","BK1583","09997","BK0216","159883","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624151657","title":"博济医药最新公告：全资子公司获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624151657","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624151657?lang=zh_cn&edition=full","pubTime":"2026-04-03 20:20","pubTimestamp":1775218803,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告称，公司全资子公司杏林中医药科技(广州)有限公司申报的“丹元糖痹软膏”获得国家药品监督管理局核准签发的《药物临床试验批准通知书》。该药品为中药1.1类创新药，适应症为糖尿病周围神经病变，具有活血行气、通络止痛功效。本次获批是新药研发的阶段性成果，不会对公司经营业绩产生重大影响。鉴于药品研发周期长、环节多，临床试验进度及结果、未来市场竞争等存在不确定性，敬请投资者注意投资风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300040171.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621095440","title":"博济医药（300404）披露已回购股份减持结果暨股份变动公告，3月24日股价上涨4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095440","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621095440?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:47","pubTimestamp":1774363634,"startTime":"0","endTime":"0","summary":"截至2026年3月24日收盘，博济医药报收于9.4元，较前一交易日上涨4.68%，最新总市值为36.27亿元。博济医药科技股份有限公司近日披露《关于已回购股份减持结果暨股份变动公告》。公告显示，公司于2026年3月24日完成回购股份的集中竞价减持，累计减持2,667,000股，占总股本0.69%，减持所得资金总额25,741,470.00元，成交均价9.65元/股。减持后回购专用账户余额为0，公司总股本不变，未导致控制权及股权结构变动。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400040387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221847","title":"博济医药（300404）披露首次减持回购股份公告，3月19日股价下跌2.74%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620221847?lang=zh_cn&edition=full","pubTime":"2026-03-19 22:33","pubTimestamp":1773930794,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，博济医药报收于9.93元，较前一交易日下跌2.74%，最新总市值为38.31亿元。近日，博济医药科技股份有限公司披露《关于首次减持回购股份的公告》。公告显示，公司于2026年3月19日通过集中竞价交易方式首次减持回购股份，减持数量为858,500股，占公司当前总股本的0.22%，成交总额为8,594,658.00元，成交均价为10.01元/股，最高价10.15元/股，最低价9.94元/股。本次减持符合公司此前披露的减持计划及相关监管规定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900039877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620565256","title":"博济医药：服务植入式脑深部刺激系统等脑科医疗器械","url":"https://stock-news.laohu8.com/highlight/detail?id=2620565256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620565256?lang=zh_cn&edition=full","pubTime":"2026-03-18 20:51","pubTimestamp":1773838302,"startTime":"0","endTime":"0","summary":"有媒体报道贵公司子公司九泰药械目前有为诸如植入式脑深部刺激系统、磁刺激调控治疗抑郁症等脑神经科学方面的医疗器械提供临床研究服务，消息是否属实。九泰药械持续关注国家政策及行业动向带来的行业机遇，提升竞争优势，并专注于为所在领域企业提供优质的医疗器械临床试验及注册申报服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800038770.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0737861772.HKD","09996","BK0216","BK1222","BK1583","06078","300404","LU0329678337.USD","LU2488822045.USD","BK1574","159883","BK1209","LU0329678170.USD","BK1100","09997"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620472207","title":"股市必读：博济医药（300404）3月17日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2620472207","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620472207?lang=zh_cn&edition=full","pubTime":"2026-03-18 02:23","pubTimestamp":1773771791,"startTime":"0","endTime":"0","summary":"截至2026年3月17日收盘，博济医药报收于9.97元，下跌1.87%，换手率1.98%，成交量5.65万手，成交额5721.81万元。当日关注点来自交易信息汇总：3月17日主力资金净流出477.46万元，散户资金净流入743.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031800001393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155133","title":"股市必读：博济医药（300404）3月12日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155133","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619155133?lang=zh_cn&edition=full","pubTime":"2026-03-13 01:33","pubTimestamp":1773336791,"startTime":"0","endTime":"0","summary":"截至2026年3月12日收盘，博济医药报收于10.06元，下跌1.57%，换手率2.1%，成交量5.99万手，成交额6052.37万元。董秘最新回复投资者： 贵公司董秘好，根据对cro板块的长期观察，结合公司业务情况，建议管理层及时跟药石科技沟通，通过发行股份或现金方式收购药石科技，壮大主业，愿采纳。当日关注点来自交易信息汇总：3月12日主力资金净流出664.88万元，散户资金净流入974.66万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300000919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616539312","title":"博济医药：2025年前三季度公司营业收入同比增长5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616539312","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616539312?lang=zh_cn&edition=full","pubTime":"2026-03-03 09:01","pubTimestamp":1772499660,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)03月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司业务发展遇到瓶颈了吗？为何营收增长速度大幅落后于其他同行？博济医药回复：您好，2025年前三季度公司营业收入同比增长5.06%，新增业务合同额同比增长约9.85%，公司营业收入及新增订单保持稳步增长。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030300007132.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613719389","title":"博济医药最新公告：拟以集中竞价方式减持不超过266.7万股回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719389","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613719389?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:29","pubTimestamp":1771936173,"startTime":"0","endTime":"0","summary":"博济医药(300404.SZ)公告称，公司于2026年2月24日召开董事会，审议通过回购股份集中竞价减持计划。根据回购报告书，公司将以集中竞价方式减持不超过266.7万股回购股份，占目前公司总股本的0.69%，减持期间为自公告发布之日起15个交易日之后六个月内。减持价格根据减持时的二级市场价格确定，所得资金将用于补充公司流动资金。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400041492.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604955261","title":"博济医药：公司重视市值管理并提升经营质量","url":"https://stock-news.laohu8.com/highlight/detail?id=2604955261","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604955261?lang=zh_cn&edition=full","pubTime":"2026-01-20 17:00","pubTimestamp":1768899636,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药01月20日在投资者关系平台上答复投资者关心的问题。公司一直专注主营业务并努力提升公司内在经营价值，也重视市值管理工作并始终将提升经营质量作为市值管理的核心，但二级市场股价受多方面因素影响，具有不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012000026017.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603951459","title":"博济医药：探索AI技术在药物研发中应用","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951459","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603951459?lang=zh_cn&edition=full","pubTime":"2026-01-16 20:52","pubTimestamp":1768567932,"startTime":"0","endTime":"0","summary":"投资者提问：请问公司在接入DeepSeek后，有没有利用AI医疗技术开展细胞基因治疗解决肿瘤问题，未来是否会用无创脑神经刺激器来研究服务阿尔兹海默症，小核酸药物等前沿领域有没有结合AI制药来提高对于创新靶点的临床研究博济医药回复：您好，公司持续关注并积极探索AI技术在药物研发中的应用，以提高新药研发的效率和质量，目前在临床前业务、临床业务均有使用，也正在探索更多应用领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600038768.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300404","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603956115","title":"博济医药：努力提升盈利能力回馈投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2603956115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603956115?lang=zh_cn&edition=full","pubTime":"2026-01-16 11:34","pubTimestamp":1768534442,"startTime":"0","endTime":"0","summary":"证券之星消息，博济医药(300404)01月15日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有为投资者创造回报的行动吗？博济医药回复：您好，管理层对公司长期发展充满信心，对公司的经营和发展从未松懈，努力提升公司盈利能力并通过持续分红等措施回馈投资者，为广大投资者创造长期价值。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011600015174.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","300404"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1781414441662,"stockEarnings":[{"period":"1week","weight":-0.0792},{"period":"1month","weight":-0.225},{"period":"3month","weight":-0.1746},{"period":"6month","weight":-0.1143},{"period":"1year","weight":-0.1142},{"period":"ytd","weight":-0.1029}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0497},{"period":"3month","weight":-0.0156},{"period":"6month","weight":0.0366},{"period":"1year","weight":0.1848},{"period":"ytd","weight":0.0158}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博济医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"31226人(较上一季度增加15.23%)","perCapita":"9143股","listingDate":"2015-04-24","address":"广东省广州市黄埔区科学城南翔一路62号(二、三、四、五)栋","registeredCapital":"38574万元","survey":" 博济医药科技股份有限公司的主营业务是为国内外制药企业及其他研究机构就新药品、医疗器械的研发与生产提供全流程“一站式”CRO服务。公司的主要产品是临床前研究服务、临床研究服务、其他咨询服务、CDMO服务。","listedPrice":12.87},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博济医药,300404,博济医药股票,博济医药股票老虎,博济医药股票老虎国际,博济医药行情,博济医药股票行情,博济医药股价,博济医药股市,博济医药股票价格,博济医药股票交易,博济医药股票购买,博济医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博济医药(300404)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博济医药(300404)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}